Market Overview

UPDATE: Morgan Stanley Downgrades Pacific Biosciences to Underweight, Reiterates $1.50 PT

Related PACB
This Week's First IPO: Global Blood Therapeutics Developing Drugs For Diseases Affecting Few
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

In a report published Monday, Morgan Stanley downgraded its rating on Pacific Biosciences of California (NASDAQ: PACB) to Underweight, and reiterated its $1.50 price target.

Morgan Stanley noted, “We expected the C2 chemistry to catalyze demand, yet bookings have sharply declined (6 in Q4, 2 in Q1, 1 in Q2). The system has unique traits and mgmt is optimistic noting signs of traction. However, weakening trends and the system's niche commercial appeal, high price, constrained funding and competitive landscape signals a more limited future potential than previously assumed. We cut our forecasts, now estimate 5 new bookings in 2H12 (prior 10) and 9 in '13 (prior 24).”

Pacific Biosciences of California closed on Friday at $2.00.

Latest Ratings for PACB

Aug 2015Cantor FitzgeraldInitiates Coverage onBuy
May 2015William BlairUpgradesMarket PerformOutperform
Mar 2015Stephens & Co.Initiates Coverage onEqualweight

View More Analyst Ratings for PACB
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Downgrades Analyst Ratings


Related Articles (PACB)

Get Benzinga's Newsletters